Li Qiang, Bagrodia Aditya, Cha Eugene K, Coleman Jonathan A
Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Urology Service, Department of Surgery, Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, 353 E. 68th Street, New York, NY, 10065, USA.
Curr Urol Rep. 2016 Feb;17(2):12. doi: 10.1007/s11934-015-0566-y.
Urothelial carcinoma is a highly heterogeneous disease that can arise throughout the entire urothelial lining from the renal pelvis to the proximal urethra. Upper tract urothelial carcinoma (UTUC) is rare, and while it shares many similarities with urothelial carcinoma of bladder (UCB), there are also significant differences between UTUC and UCB regarding clinical management and outcomes. No major advances have been made recently in the development of new systemic therapies for urothelial carcinoma, partly due to the lack of understanding of underlying molecular pathogenetic mechanisms. In the past decade, the emergence of next-generation sequencing has greatly enabled genomic characterization of tumor samples. Researchers are currently exploring a personalized approach to augment traditional clinical decision-making based on genetic alterations. In the present review, we summarize current genomic advances in UTUC and discuss the potential implications of these developments for developing prognostic and predictive biomarkers.
尿路上皮癌是一种高度异质性疾病,可发生于从肾盂到近端尿道的整个尿路上皮内衬。上尿路尿路上皮癌(UTUC)较为罕见,虽然它与膀胱尿路上皮癌(UCB)有许多相似之处,但在临床管理和预后方面,UTUC与UCB之间也存在显著差异。尿路上皮癌新的全身治疗方法最近没有取得重大进展,部分原因是对潜在分子致病机制缺乏了解。在过去十年中,新一代测序技术的出现极大地推动了肿瘤样本的基因组特征分析。研究人员目前正在探索一种个性化方法,以基于基因改变增强传统临床决策。在本综述中,我们总结了UTUC目前的基因组进展,并讨论了这些进展对开发预后和预测生物标志物的潜在影响。